Sun Pharmaceutical Industries’ shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in women’s health. This strategic move aims to bolster Sun Pharma’s innovative medicines business and establish it as a top-tier player in biosimilars and women’s health globally.
Rising input costs continue to pressure Reliance’s O2C business: Yogesh Patil
Reliance Industries navigates tough market conditions. Refining margins face volatility due to rising costs. Global crack spreads show improvement, but structural issues persist. The company’s